Phaseline

Targets › PDE6A

PDE6A (Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Jul 2027.

Catalytic alpha subunit of the rod-specific cGMP phosphodiesterase (PDE6) complex, which hydrolyzes 3',5'-cyclic GMP in the phototransduction cascade. The PDE6 holoenzyme consists of two catalytic subunits (PDE6A and PDE6B) and two inhibitory gamma subunits (PDE6G). (UniProt, P16499)

Open in Phaseline: the race on PDE6A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
STZ eyetrialrAAV.hPDE6A
Recombinant adeno-associated viral vector delivering human PDE6A gene to restore rod phosp
PDE6APhase 1Retinitis PigmentosaJul 2027

Conditions

Retinitis Pigmentosa (1)

Modalities

other (1)

Companies

STZ eyetrial (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.